Refers to an antibody pharmacology mixture (ADC) including formula structure (x),Or salt, the formula (x) contains an anti EGFR (AB) antibody and a cytotoxic agent, wherein the anti EGF antibody includes a variable region in the heavy chain, including a CDR1 sequence, including sec No.: 3, and a CDR2 sequence, including sec No.: 4, And a CDR3 sequence, including sec No.: 5； a light chain variable region, including a CDR1 sequence, including SEQ ID number: 8； a CDR2 sequence, including SEQ ID number: 9 and a CDR3 sequence, including SEQ ID number: 10； and a mutation, including s239c of the heavy chain constant region,The number is consistent with Kabat, where the anti bad person antibody binds to the cytotoxic agent through mutations, including s239c, and N is 2. This combination of antigenic prescriptions immobilizes the human immunodeficiency syndrome and is useful in cancer treatment. He also mentioned a pharmacology composer, which included an antibody pharmacology combination.Referida a un conjugado anticuerpo-farmaco (ADC) que comprende la estructura de formula (X), o una sal del mismo, en donde la formula (X) comprende un anticuerpo anti-EGFR (Ab) conjugado con un agente citotoxico, en donde el anticuerpo anti-EGFR comprende: una region variable de la cadena pesada que comprende una secuencia CDRH1 que comprende la SEC ID NO: 3, una secuencia CDRH2 que comprende la SEC ID NO: 4, y una secuencia CDRH3 que comprende la SEC ID NO: 5； una region variable de la cadena ligera que comprende una secuencia CDRL1 que comprende la SEQ ID NO: 8, una secuencia CDRL2 que comprende la SEQ ID NO: 9 y una secuencia CDRL3 que comprende la SEQ ID NO: 10； y una mutacion que comprende S239C en una region constante de cadena pesada, en la que la numeracion esta de acuerdo con Kabat； en donde el anticuerpo anti-EGFR se conjuga con un agente citotoxico a traves de la mutacion que comprende S239C, y en donde n es 2. Dicho conjugado anticuerpo-farmaco se fija al EGFR humano, siendo uti
